{"id":1208,"date":"2025-07-04T09:48:21","date_gmt":"2025-07-04T09:48:21","guid":{"rendered":"http:\/\/xenopat.com\/projectes\/"},"modified":"2025-07-14T12:26:04","modified_gmt":"2025-07-14T12:26:04","slug":"projectes","status":"publish","type":"page","link":"http:\/\/xenopat.com\/ca\/projectes\/","title":{"rendered":"Projectes"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Projectes<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tNom del projecte<\/strong>

Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics.\u00a0(EVEREST)\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tFinanciat per<\/strong>

MSCA Staff Exchanges 2023<\/b>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

Les ves\u00edcules extracel\u00b7lulars (VE) s\u00f3n petites ves\u00edcules unides a la membrana que les c\u00e8l\u00b7lules alliberen al medi extracel\u00b7lular. Les VE intervenen en diversos processos fisiol\u00f2gics i patol\u00f2gics, com la resposta immunit\u00e0ria, la progressi\u00f3 del c\u00e0ncer i la reparaci\u00f3 de teixits. Amb el suport del programa Marie Sk\u0142odowska-Curie Actions, el projecte EVEREST pret\u00e9n normalitzar l\u2019a\u00efllament i la caracteritzaci\u00f3 de les VE. Els investigadors estudiaran les funcions de les VE en la salut i la malaltia, promovent-les com a biomarcadors i vehicles d\u2019administraci\u00f3 de f\u00e0rmacs. L\u2019objectiu a llarg termini \u00e9s avan\u00e7ar en la terap\u00e8utica basada en les VE i posicionar-les com a eines essencials per a la medicina personalitzada.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/cordis.europa.eu\/project\/id\/101183034<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/everest-consortium.com\/<\/span><\/a><\/p>\n

<\/p>\n

https:\/\/www.linkedin.com\/company\/everest-consortium\/<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.instagram.com\/everestconsortium\/#<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/bsky.app\/profile\/everestconsortium.bsky.social<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.ucd.ie\/newsandopinion\/news\/2024\/november\/08\/ucd-ledeuprojecteverestaimstotransformcancerandcardiovasculardiagnosisandcare\/<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

En curs<\/span><\/p>\n

 <\/p>\n

Duraci\u00f3 del projecte: 1 gener 2025 \u2013 31 desembre 2028<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tNom del projecte<\/strong>

New In Vitro <\/i>Pre-Screening Platform Service: Patient-Derived Orthotopic Xenografts In Vitro <\/i>Models\u00a0<\/span>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tFinanciat per<\/strong>

Doctorados Industriales, Ministerio de Ciencia Innovaci\u00f3n y Universidades\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

Reconeguda pel seu extens banc de models PDX d\u2019alta qualitat, Xenopat est\u00e0 desenvolupant un nou servei de preselecci\u00f3 in vitro per millorar l\u2019efici\u00e8ncia de la recerca precl\u00ednica de f\u00e0rmacs oncol\u00f2gics. L\u2019objectiu del servei \u00e9s reduir l\u2019\u00fas d\u2019animals i, alhora, mantenir el poder predictiu dels models PDX, en conson\u00e0ncia amb el principi de les 3 erres i els recents canvis normatius. En millorar l\u2019avaluaci\u00f3 dels f\u00e0rmacs en les primeres fases, el projecte afavorir\u00e0 una entrada m\u00e9s segura i efica\u00e7 als assaigs cl\u00ednics.<\/p>\n

\u00a0<\/span><\/p>\n

En curs<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Duraci\u00f3 del projecte: 1 octubre 2024 \u2013 1 octubre 2028<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

Millora dels estudis precl\u00ednics per provar nous f\u00e0rmacs oncol\u00f2gics: establiment de l\u00ednies cel\u00b7lulars a partir de xenoemplants derivats del pacient (PDX)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

Doctorat Industrial AGAUR<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

L\u2019objectiu d\u2019aquest projecte de doctorat \u00e9s desenvolupar un m\u00e8tode de cribratge previ in vitro utilitzant l\u00ednies cel\u00b7lulars derivades de xenografts derivats de pacients (PDX). Aix\u00f2 ajudar\u00e0 a reduir l\u2019\u00fas d\u2019animals en oncologia precl\u00ednica. En validar la similitud de les l\u00ednies cel\u00b7lulars amb els PDX originals, el m\u00e8tode millorar\u00e0 la selecci\u00f3 de f\u00e0rmacs i l\u2019efic\u00e0cia dels estudis. Aquest m\u00e8tode afavoreix el desenvolupament de ter\u00e0pies contra el c\u00e0ncer m\u00e9s r\u00e0pides i segures i s\u2019ajusta als aven\u00e7os \u00e8tics i normatius.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

En curs<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

Duraci\u00f3 del projecte: 1 octubre 2024 \u2013 1 octubre 2027<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

Next generation Peptide Drug Conjugate as a novel tumour specific treatment for glioblastoma patients.\u00a0(GlioPep)<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

EUROSTARS-3, CDTI<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Description<\/b><\/p>\n

GLIOPEP, un projecte finan\u00e7at per Eurostars-Eureka (Eureka Network<\/b><\/span><\/a>) i cofinan\u00e7at pel programa\u00a0HorizonEurope<\/b><\/span><\/a> de la UE, \u00e9s una iniciativa de recerca atractiva centrada en el desenvolupament d\u2019una nova quimioter\u00e0pia antitumoral per al glioblastoma, un dels tumors cerebrals m\u00e9s agressius per al qual actualment no existeix un tractament curatiu.<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/www.vinnova.se\/en\/p\/e2328-gliopep—next-generation-peptide-drug-conjugate-as-a-novel-tumour-specific-treatment-for-glioblastoma-patients-oncopeptides-ab\/?utm_source=chatgpt.com<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

En curs<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/span><\/p>\n

<\/p>\n

Duraci\u00f3 del projecte: mar\u00e7 2023 \u2013 mar\u00e7 2026<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte
\n<\/strong>Building a reproducible single-cell experimental workflow to capture tumour drug persistence. (PERSIST-SEQ)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

Innovative Medicines Initiative 2 (IMI), European Union\u2019s Horizon 2020 research and innovation programme and EFPIA<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

L\u2019objectiu de PERSIST-SEQ \u00e9s aportar noves dades sobre els mecanismes que subjauen a la resist\u00e8ncia al tractament. Per a aix\u00f2, es desenvolupar\u00e0 un enfocament estandarditzat per estudiar i seq\u00fcenciar el codi gen\u00e8tic de c\u00e8l\u00b7lules canceroses individuals abans, durant i despr\u00e9s del tractament. En total, el projecte preveu utilitzar tecnologia capdavantera per caracteritzar 5 milions de c\u00e8l\u00b7lules i se centrar\u00e0 principalment en el c\u00e0ncer de pulm\u00f3, colorectal i de mama.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/www.ihi.europa.eu\/projects-results\/project-factsheets\/persist-seq<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/persist-seq.org\/<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.linkedin.com\/company\/persist-seq\/posts\/?feedView=all<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/x.com\/persistseq<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

En curs<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/span><\/p>\n

<\/p>\n

Duraci\u00f3 del projecte: 1 juliol 2021 \u2013 30 juny 2026<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tNom del projecte<\/strong>

Development of a T14 Inhibitor for Treatment of ColoRectal Cancer\u00a0 <\/span>

 

(DEFIT-CRC )

 \t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

Tecniospring, el programa internacional de talent d\u2019ACCI\u00d3, ofereix a empreses i centres tecnol\u00f2gics l\u2019oportunitat de desenvolupar projectes transformadors mitjan\u00e7ant la contractaci\u00f3 de personal qualificat en R+D.<\/p>\n

DEFIT-CRC t\u00e9 com a objectiu desenvolupar un nou f\u00e0rmac antitumoral i\/o antimetast\u00e0tic per a pacients amb c\u00e0ncer colorectal (CCR).<\/p>\n

\u00a0<\/span><\/p>\n

https:\/\/www.accio.gencat.cat\/ca\/accio\/premsa-comunicacio\/cercador-premsa-actualitat\/article\/20250427-empresa-catalana-xenopat-desenvolupament-farmac-frenar-metastasi-cancer-colorectal-medicament-alzheimer<\/a><\/p>\n

https:\/\/lanitdelarecerca.cat\/development-of-a-t14-inhibitor-for-treatment-of-colorectal-cancer-defit-crc\/<\/a><\/p>\n

https:\/\/cordis.europa.eu\/project\/id\/801342<\/a><\/p>\n

 <\/p>\n

Projecte finalitzat<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

Duraci\u00f3 del projecte: 1 mar\u00e7 2022 \u2013 17 octubre 2024<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

New Theranostic Nanobody for CMS4 Colorectal Cancer: Selective PET Imaging and Targeted Radiotherapy. (ColoSelect)<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tFinanciat per<\/strong>

Eurostars-2 programme, EU-H2020, CDTI\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

Al voltant del 23% dels pacients amb c\u00e0ncer colorectal (CCR) tenen el subtipus CMS4, que \u00e9s la forma m\u00e9s agressiva. Es caracteritza per una met\u00e0stasi r\u00e0pida, resist\u00e8ncia a la quimioter\u00e0pia i una baixa taxa de superviv\u00e8ncia al cap de cinc anys. ColoSelect desenvolupa BOT1700, el primer nanoc\u00f2s teran\u00f2stic per al CMS4-CCR. S\u2019adre\u00e7a al receptor PDGF-beta, que est\u00e0 sobreexpressat a l\u2019estroma fibr\u00f2tic dels tumors CMS4, i pot utilitzar-se tant per a l\u2019obtenci\u00f3 d\u2019imatges PET com per a la radioter\u00e0pia dirigida. Una prova de concepte precl\u00ednica avaluar\u00e0 el seu \u00fas diagn\u00f2stic, seguida d\u2019una validaci\u00f3 terap\u00e8utica.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/www.era-learn.eu\/network-information\/networks\/eurostars-2\/eurostars-cut2013off-14\/new-theranostic-nanobody-for-cms4-colorectal-cancer-selective-pet-imaging-and-targeted-radiotherapy<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

Projecte finalitzat<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/span><\/p>\n

<\/p>\n

Duraci\u00f3 del projecte: <\/span>1 abril 2021 \u2013 31 gener 2024<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

Commercial & Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease.\u00a0(CRYSTAL3)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

EU-H2020 MSCA RISE<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

CRYSTAL3<\/strong> \u00e9s un consorci internacional (12 membres de 8 pa\u00efsos, liderat pel University College de Dubl\u00edn) finan\u00e7at pel programa Horizon 2020 MSCA RISE de la UE (GA 101007931) amb 887.800 euros per investigar les CysLT, una via de senyalitzaci\u00f3 cel\u00b7lular relativament inexplorada que es troba en diverses malalties humanes.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/cordis.europa.eu\/project\/id\/101007931<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.ucd.ie\/crystal3\/<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.ucd.ie\/crystal3\/project\/<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/x.com\/Crystal3Project<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

Projecte finalitzat<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

Duraci\u00f3 del projecte:<\/span> 1 gener 2021 \u2013 31 desembre 2024<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

A novel targeted treatment against ovarian cancer.\u00a0(nOVAB)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

Eurostars-2 programme, EU-H2020, CDTI<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

L\u2019objectiu de nOVAB era desenvolupar una ter\u00e0pia amb un antic\u00f2s monoclonal (mAb)<\/strong>, el primer de la seva classe, dirigit a un ep\u00edtop espec\u00edfic d\u2019un tumor identificat recentment. Aquest antic\u00f2s bloqueja una nova diana oncol\u00f2gica, desencadenant la mort de les c\u00e8l\u00b7lules canceroses i reduint significativament el creixement del tumor a trav\u00e9s d\u2019una via oncog\u00e8nica \u00fanica.<\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

https:\/\/www.vinnova.se\/p\/e113292-novab-goteborgs-universitet\/<\/a><\/span><\/p>\n

<\/p>\n

https:\/\/www.era-learn.eu\/network-information\/networks\/eurostars-2\/eurostars-cut2013off-11\/a-novel-targeted-treatment-against-ovarian-cancer<\/a><\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

Projecte finalitzat<\/span><\/p>\n

<\/p>\n

\u00a0<\/span><\/p>\n

<\/p>\n

Duraci\u00f3 del projecte:<\/span> 1<\/span> octubre 2019 – 3 octubre 2022<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics.
\n(3D NEONET)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

EU-H2020 MSCA RISE<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

3D NEONET \u00e9s un consorci que reuneix un grup \u00fanic d\u2019investigadors de 18 institucions de 7 pa\u00efsos diferents, unint esfor\u00e7os per accelerar el desenvolupament d\u2019intervencions terap\u00e8utiques per a oncologia i oftalmologia.<\/p>\n

https:\/\/cordis.europa.eu\/project\/id\/734907\/results<\/a><\/p>\n

https:\/\/www.youtube.com\/watch?v=w6ZDxaimGQA https:\/\/x.com\/3dneonet<\/a><\/p>\n

\u00a0<\/span><\/p>\n

Projecte finalitzat<\/span><\/p>\n

 <\/p>\n

Durada del projecte: 1 gener 2017 \u2013 30 juny 2022<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

MaxiMice<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

StartUp Capital ACCI\u00d3<\/span><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

Xenopat posa en marxa un nou servei d\u2019assessorament personalitzat per al tractament del c\u00e0ncer. La creaci\u00f3 d\u2019un orthoxenograft espec\u00edfic per a cada pacient permet provar la ter\u00e0pia m\u00e9s adequada en cada moment per al seu cas particular. El servei es va desenvolupar com a prova de concepte, amb la primera factura emesa el juliol de 2017. Aquest projecte pret\u00e9n accelerar la penetraci\u00f3 en el mercat d\u2019aquest nou servei.<\/p>\n

https:\/\/www.accio.gencat.cat\/ca\/accio\/premsa-comunicacio\/cercador-premsa-actualitat\/article\/180222-20-startups-catalanes-reben-un-ajut-de-75000-euros<\/a><\/p>\n

 <\/p>\n

Projecte finalitzat<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Duraci\u00f3 del projecte: 7 setembre 2017 \u2013 30 juliol 2020<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Nom del projecte<\/strong><\/p>\n

EPIgenetics of PHARMacogenetics.\u00a0(EpiPharm)<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Financiat per<\/strong><\/p>\n

EXCELLENT SCIENCE – European Research Council (ERC), Proof of Concept (PoC) Grants<\/strong><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Descripci\u00f3 del projecte<\/b><\/p>\n

EPIPHARM \u00e9s un projecte de recerca innovador centrat en el desenvolupament d\u2019un kit de metilaci\u00f3 del DNA dirigit a regions de RNA no codificant (ncRNA) per donar suport a la presa de decisions en el tractament del c\u00e0ncer d\u2019origen primari desconegut (CUP). L\u2019objectiu \u00e9s crear una eina d\u2019epigenotipat d\u2019alt Duraci\u00f3 del projectecapa\u00e7 d\u2019identificar una empremta de sensibilitat a f\u00e0rmacs basada en el perfil de metilaci\u00f3 del DNA dels loci de ncRNA.<\/p>\n

https:\/\/cordis.europa.eu\/project\/id\/727264<\/a><\/p>\n

 <\/p>\n

Projecte finalitzat<\/span><\/p>\n

 <\/p>\n

Duraci\u00f3 del projecte: 1 febrer 2017 \u2013 31 juliol 2018<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Projectes Nom del projecte Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics.\u00a0(EVEREST) Financiat per MSCA Staff Exchanges 2023 Descripci\u00f3 del projecte Les ves\u00edcules extracel\u00b7lulars (VE) s\u00f3n petites ves\u00edcules unides a la membrana que les c\u00e8l\u00b7lules alliberen al medi extracel\u00b7lular. Les VE intervenen en diversos processos fisiol\u00f2gics i patol\u00f2gics, com la resposta immunit\u00e0ria, la progressi\u00f3 […]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1208","page","type-page","status-publish","hentry"],"yoast_head":"\nProjectes - Xenopat<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/xenopat.com\/projects\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Projectes - Xenopat\" \/>\n<meta property=\"og:description\" content=\"Projectes Nom del projecte Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics.\u00a0(EVEREST) Financiat per MSCA Staff Exchanges 2023 Descripci\u00f3 del projecte Les ves\u00edcules extracel\u00b7lulars (VE) s\u00f3n petites ves\u00edcules unides a la membrana que les c\u00e8l\u00b7lules alliberen al medi extracel\u00b7lular. Les VE intervenen en diversos processos fisiol\u00f2gics i patol\u00f2gics, com la resposta immunit\u00e0ria, la progressi\u00f3 […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/xenopat.com\/projects\/\" \/>\n<meta property=\"og:site_name\" content=\"Xenopat\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T12:26:04+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/xenopat.com\/projects\/\",\"url\":\"http:\/\/xenopat.com\/projects\/\",\"name\":\"Projectes - Xenopat\",\"isPartOf\":{\"@id\":\"http:\/\/xenopat.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/xenopat.com\/projects\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/xenopat.com\/projects\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png\",\"datePublished\":\"2025-07-04T09:48:21+00:00\",\"dateModified\":\"2025-07-14T12:26:04+00:00\",\"breadcrumb\":{\"@id\":\"http:\/\/xenopat.com\/projects\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/xenopat.com\/projects\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"http:\/\/xenopat.com\/projects\/#primaryimage\",\"url\":\"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png\",\"contentUrl\":\"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/xenopat.com\/projects\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/xenopat.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projectes\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/xenopat.com\/#website\",\"url\":\"http:\/\/xenopat.com\/\",\"name\":\"Xenopat\",\"description\":\"The latest scientific findings at the service of the fight against cancer\",\"publisher\":{\"@id\":\"http:\/\/xenopat.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/xenopat.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"http:\/\/xenopat.com\/#organization\",\"name\":\"Xenopat\",\"url\":\"http:\/\/xenopat.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"http:\/\/xenopat.com\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/xenopat.com\/wp-content\/uploads\/2020\/03\/cropped-xenopat_normal.png\",\"contentUrl\":\"http:\/\/xenopat.com\/wp-content\/uploads\/2020\/03\/cropped-xenopat_normal.png\",\"width\":141,\"height\":23,\"caption\":\"Xenopat\"},\"image\":{\"@id\":\"http:\/\/xenopat.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Projectes - Xenopat","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/xenopat.com\/projects\/","og_locale":"ca_ES","og_type":"article","og_title":"Projectes - Xenopat","og_description":"Projectes Nom del projecte Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics.\u00a0(EVEREST) Financiat per MSCA Staff Exchanges 2023 Descripci\u00f3 del projecte Les ves\u00edcules extracel\u00b7lulars (VE) s\u00f3n petites ves\u00edcules unides a la membrana que les c\u00e8l\u00b7lules alliberen al medi extracel\u00b7lular. Les VE intervenen en diversos processos fisiol\u00f2gics i patol\u00f2gics, com la resposta immunit\u00e0ria, la progressi\u00f3 […]","og_url":"http:\/\/xenopat.com\/projects\/","og_site_name":"Xenopat","article_modified_time":"2025-07-14T12:26:04+00:00","og_image":[{"url":"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/xenopat.com\/projects\/","url":"http:\/\/xenopat.com\/projects\/","name":"Projectes - Xenopat","isPartOf":{"@id":"http:\/\/xenopat.com\/#website"},"primaryImageOfPage":{"@id":"http:\/\/xenopat.com\/projects\/#primaryimage"},"image":{"@id":"http:\/\/xenopat.com\/projects\/#primaryimage"},"thumbnailUrl":"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png","datePublished":"2025-07-04T09:48:21+00:00","dateModified":"2025-07-14T12:26:04+00:00","breadcrumb":{"@id":"http:\/\/xenopat.com\/projects\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["http:\/\/xenopat.com\/projects\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"http:\/\/xenopat.com\/projects\/#primaryimage","url":"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png","contentUrl":"http:\/\/xenopat.com\/wp-content\/uploads\/2025\/06\/logo-everest.png"},{"@type":"BreadcrumbList","@id":"http:\/\/xenopat.com\/projects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/xenopat.com\/"},{"@type":"ListItem","position":2,"name":"Projectes"}]},{"@type":"WebSite","@id":"http:\/\/xenopat.com\/#website","url":"http:\/\/xenopat.com\/","name":"Xenopat","description":"The latest scientific findings at the service of the fight against cancer","publisher":{"@id":"http:\/\/xenopat.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/xenopat.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"http:\/\/xenopat.com\/#organization","name":"Xenopat","url":"http:\/\/xenopat.com\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"http:\/\/xenopat.com\/#\/schema\/logo\/image\/","url":"http:\/\/xenopat.com\/wp-content\/uploads\/2020\/03\/cropped-xenopat_normal.png","contentUrl":"http:\/\/xenopat.com\/wp-content\/uploads\/2020\/03\/cropped-xenopat_normal.png","width":141,"height":23,"caption":"Xenopat"},"image":{"@id":"http:\/\/xenopat.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/pages\/1208"}],"collection":[{"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/comments?post=1208"}],"version-history":[{"count":15,"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/pages\/1208\/revisions"}],"predecessor-version":[{"id":1349,"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/pages\/1208\/revisions\/1349"}],"wp:attachment":[{"href":"http:\/\/xenopat.com\/ca\/wp-json\/wp\/v2\/media?parent=1208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}